Clinical Trials
69 trialsA Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
MEMMAT
Medical University of Vienna
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
CAV Regimen for R/R Ph- B-ALL
The First Affiliated Hospital of Soochow University
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
University of Maryland, Baltimore
DEXAML-03
University Hospital, Toulouse
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
VHAG in Treating R/R T-ALL/LBL
First Affiliated Hospital of Zhejiang University
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Children's Hospital of Soochow University
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
University of California, San Francisco
AC220 for Children With Relapsed/Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
GSO Global Clinical Research BV
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Therapeutic Advances in Childhood Leukemia Consortium
FLAGINEXOR
PETHEMA Foundation
Japanese AML
Gilead Sciences
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Therapeutic Advances in Childhood Leukemia Consortium
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
TRANSATRA
University Hospital Freiburg
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Asan Medical Center
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center